196 related articles for article (PubMed ID: 36961395)
1. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
[TBL] [Abstract][Full Text] [Related]
2. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
3. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
Zhang D; Wang T; Zhou Y; Zhang X
Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
[TBL] [Abstract][Full Text] [Related]
6. Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers.
Yang J; Liu Y; Geng Q; Wang B
Mol Biol Rep; 2024 May; 51(1):670. PubMed ID: 38787485
[TBL] [Abstract][Full Text] [Related]
7. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.
Zhao R; Choi BY; Lee MH; Bode AM; Dong Z
EBioMedicine; 2016 Jun; 8():30-39. PubMed ID: 27428416
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies.
Sun A; Cai F; Xiong Q; Xie T; Li X; Xie Y; Luo R; Hu W; Zhong F; Wang S
Front Mol Biosci; 2023; 10():1277830. PubMed ID: 37942289
[No Abstract] [Full Text] [Related]
11. Transcriptional regulation of
Rodríguez S; Bermúdez LG; González D; Bernal C; Cañas A; Morales-Ruíz T; Henríquez B; Rojas A
Mol Med Rep; 2022 Nov; 26(5):. PubMed ID: 36169180
[TBL] [Abstract][Full Text] [Related]
12.
Adib E; Nassar AH; Akl EW; Abou Alaiwi S; Nuzzo PV; Mouhieddine TH; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Shukla SA; Gusev A; Braun DA; Choueiri TK; Kwiatkowski DJ
Clin Cancer Res; 2021 Jul; 27(14):4025-4035. PubMed ID: 34074656
[TBL] [Abstract][Full Text] [Related]
13. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.
Zhang D; Jiang Z; Hu J; Sun X; Zheng Y; Shen Y
Front Immunol; 2023; 14():1117585. PubMed ID: 37251370
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
[TBL] [Abstract][Full Text] [Related]
15. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
16. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of E2F6 in cancer prognosis and responses of immunotherapy.
Gong C; Tu Z; Long X; Liu X; Liu F; Liu J; Zhu X; Li J; Huang K
Int Immunopharmacol; 2024 Jan; 127():111302. PubMed ID: 38071912
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis Revealed that
Chen Z; Guo Y; Zhao D; Zou Q; Yu F; Zhang L; Xu L
Front Cell Dev Biol; 2021; 9():808208. PubMed ID: 35004697
[TBL] [Abstract][Full Text] [Related]
19. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
20. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
